ClinicalTrials.gg
CompletedNCT03662620Updated Nov 12, 2024

Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers

A Phase 1 interventional study of Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg and Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg in Hypertension, sponsored by Yuhan Corporation. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-12.

Sponsored by Yuhan Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.

Enrollment
70th of 99
67 · median 184
Started
2018
with 1 other
Phase 1
15 of 99
none open now
Registered
82nd of 99
by date
Lead sponsor
2 of 99
Yuhan Corporation

Among the 99 studies testing telmisartan in Hypertension, this one is the 70th largest by enrollment, is one of 2 that started in 2018, is one of 15 in phase 1, and was the 82nd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 19 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies testing telmisartan in Hypertension, or all of them as a file.
02

Study summary

This is a phase 1, randomized, open label, single-dose, replicate crossover clinical trial to compare the safety and pharmacokinetics of YH22162 in healthy male volunteers.

Hypothesis: Study drug and comparator drug are showing equal pharmacokinetics.

Read the detailed description

In ARM1, 32 subjects will be assigned and the subjects will be administered "comparator drug" at Day1/Day43 and "study drug" at Day22/64.

In ARM2, 32 subjects will be assigned and the subjects will be administered "study drug" at Day1/Day43 and "comparator drug" at Day22/64.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male with (BMI) between 18.5 and 30 kg/m2
  • Who has not suffered from disease
  • Provision of signed written

Exclusion criteria

Exclusion Criteria:

  • History of and disease
  • Administration of other products within 3 months prior to the first dosing
  • Volunteers considered not eligible for the clinical trial by the investigator due to reasons including laboratory test results, ECGs, or vital signs
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    ARM1

    In ARM1, 32 subjects will be assigned and the subjects will be administered "comparator drug" at Day1/Day43 and "study drug" at Day22/64.

    Drug: Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg

  • Experimental
    ARM2

    In ARM2, 32 subjects will be assigned and the subjects will be administered "study drug" at Day1/Day43 and "comparator drug" at Day22/64.

    Drug: Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg

Interventions

  • DrugTelmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg

    Drug page: Telmisartan

    White colored oval three-layer tablet

    Also known as: Study drug

  • DrugTelmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg

    Drug page: Telmisartan

    White and pink colored oval two-layer tablet

    Also known as: Comparator drug

06

What researchers measure

Primary outcomes

  1. AUClast of Telmisartan/amlodipine/chlorthalidone

    AUClast

    Time frame: 0-168 hrs

  2. Cmax of Telmisartan/amlodipine/chlorthalidone

    Cmax

    Time frame: 0-168 hrs

Secondary outcomes

  1. AUCinf of Telmisartan/amlodipine/chlorthalidone

    AUCinf

    Time frame: 0-168 hrs

  2. Tmax of Telmisartan/amlodipine/chlorthalidone

    Tmax

    Time frame: 0-168 hrs

  3. t1/2 of Telmisartan/amlodipine/chlorthalidone

    t1/2

    Time frame: 0-168 hrs

07

Study locations

1 site
  • Chonbuk National University Hospital
    Jeonju, Jeollanam-do 54907, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Dec 2018, 2 months.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 2 months is close to that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2018
First posted
Sep 7, 2018
StartActual
Oct 5, 2018
Primary completionActual
Dec 8, 2018
CompletionActual
Dec 22, 2018
Last update
Nov 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03662620
Lead sponsor
Yuhan Corporation
Responsible party
Sponsor
First posted
Sep 7, 2018
Start date
Oct 5, 2018
Primary completion
Dec 8, 2018
Completion
Dec 22, 2018
Last update
Nov 12, 2024

Study contacts

Mingul Kim, MD
principal investigator · Chonbuk National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telmisartan

Start the discussion